7.76
-0.29(-3.60%)
Currency In USD
| Previous Close | 8.05 |
| Open | 7.93 |
| Day High | 7.87 |
| Day Low | 7.76 |
| 52-Week High | 49.27 |
| 52-Week Low | 5.36 |
| Volume | 26,300 |
| Average Volume | 61,938 |
| Market Cap | 27.32M |
| PE | -0.4 |
| EPS | -19.5 |
| Moving Average 50 Days | 9.66 |
| Moving Average 200 Days | 13.95 |
| Change | -0.29 |
If you invested $1000 in Tempest Therapeutics, Inc. (TPST) 10 years ago, it would be worth $1.22 as of April 27, 2025 at a share price of $7.76. Whereas If you bought $1000 worth of Tempest Therapeutics, Inc. (TPST) shares 5 years ago, it would be worth $327.43 as of April 27, 2025 at a share price of $7.76.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP
GlobeNewswire Inc.
Apr 21, 2025 12:00 PM GMT
BRISBANE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that the U.
Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value
GlobeNewswire Inc.
Apr 09, 2025 8:30 PM GMT
Amezalpat (TPST-1120) is Phase 3-ready: completed FDA and EMA interactions for first-line pivotal study in hepatocellular carcinoma (HCC); global investigator support in placeAwarded both Orphan Drug & Fast Track designations for amezalpat based on p
Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting
GlobeNewswire Inc.
Mar 25, 2025 8:30 PM GMT
Clinical data supporting mechanism of action reinforce potential as a novel cancer treatmentBRISBANE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-c